...
首页> 外文期刊>Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation >Canine bone marrow-derived mesenchymal stromal cells suppress alloreactive lymphocyte proliferation in vitro but fail to enhance engraftment in canine bone marrow transplantation.
【24h】

Canine bone marrow-derived mesenchymal stromal cells suppress alloreactive lymphocyte proliferation in vitro but fail to enhance engraftment in canine bone marrow transplantation.

机译:犬骨髓来源的间充质基质细胞在体外抑制同种异体淋巴细胞增殖,但不能增强犬骨髓移植中的植入。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Stable mixed hematopoietic chimerism has been consistently established in dogs who were mildly immunosuppressed by 200 cGy of total body irradiation (TBI) before undergoing dog leukocyte antigen (DLA)-identical bone marrow (BM) transplantation and who received a brief course of immunosuppression with mycophenolate mofetil (28 days) and cyclosporine (35 days) after transplantation. However, when TBI was reduced from 200 to 100 cGy, grafts were nearly uniformly rejected within 3-12 weeks. Here, we asked whether stable engraftment could be accomplished after a suboptimal dose of 100 cGy TBI with host immunosuppression enhanced by donor-derived mesenchymal stromal cells (MSCs) given after transplantation. MSCs were cultured from BM cells and evaluated in vitro for antigen expression. They showed profound immunosuppressive properties in mixed lymphocyte reactions (MLRs) in a cell dose-dependent manner not restricted by DLA. MSC and lymphocyte contact was not required, indicating that immunosuppression was mediated by soluble factors. Prostaglandin E2 was increased in culture supernatant when MSCs were cocultured in MLRs. The addition of indomethacin restored lymphocyte proliferation in cultures containing MSCs. MSCs expressed CD10, CD13, CD29, CD44, CD73/SH-3, CD90/Thy-1, and CD106/VCAM-1. For in vivo studies, MSCs were injected on the day of BM grafting and on day 35, the day of discontinuation of posttransplantation cyclosporine. MSCs derived from the respective BM donors failed to avert BM graft rejection in 4 dogs who received DLA-identical grafts after nonmyeloablative conditioning with 100 cGy TBI in a time course not significantly different from that of control dogs not given MSCs. Although the MSCs displayed in vitro characteristics similar to those reported for MSCs from other species, their immunosuppressive qualities failed to sustain stable BM engraftment in vivo in this canine model.
机译:稳定的混合造血嵌合体已在狗身上经历了稳定的混合造血嵌合体,这些狗在接受狗白细胞抗原(DLA)-相同的骨髓(BM)移植之前受到了200 cGy的全身辐射(TBI)的轻微免疫抑制,并且接受了霉酚酸酯的短暂免疫抑制过程Mofetil(28天)和环孢素(35天)移植后。但是,当TBI从200 cGy降低到100 cGy时,移植物在3-12周内几乎被均匀排斥。在这里,我们问到100 cGy TBI剂量低于最佳剂量后,移植后给予供体来源的间充质基质细胞(MSC)可以增强宿主的免疫抑制作用,是否可以实现稳定的移植。从BM细胞培养MSC,并在体外评估抗原表达。他们以不受剂量限制的细胞剂量依赖性方式在混合淋巴细胞反应(MLR)中显示出深远的免疫抑制特性。不需要MSC和淋巴细胞接触,这表明免疫抑制是由可溶性因子介导的。当在MLRs中共培养MSC时,培养上清液中的前列腺素E2增加。消炎痛的添加在含有MSC的培养物中恢复了淋巴细胞的增殖。 MSC表达CD10,CD13,CD29,CD44,CD73 / SH-3,CD90 / Thy-1和CD106 / VCAM-1。为了进行体内研究,在BM移植当天和移植后环孢素终止后的第35天注射MSC。分别取自BM供体的MSC未能避免4只在接受100 cGy TBI的非清髓性调理后接受DLA相同移植物的狗中BM移植物排斥,其时间过程与未给予MSC的对照狗无明显差异。尽管MSCs的体外特性与其他物种的MSCs相似,但在这种犬模型中,其免疫抑制特性未能在体内维持稳定的BM植入。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号